Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.

@article{Minami2008PhaseIA,
  title={Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.},
  author={Hironobu Minami and Kenji Kawada and Hiromichi Ebi and Koichi Kitagawa and Yon-il Kim and Kazuhiro Araki and Hirofumi Mukai and Makoto Tahara and Hikaru Nakajima and Keiko Nakajima},
  journal={Cancer science},
  year={2008},
  volume={99 7},
  pages={1492-8}
}
Sorafenib is a novel oral multikinase inhibitor that targets Raf serine/threonine and receptor tyrosine kinases, and inhibits tumor cell proliferation and angiogenesis. We have conducted a phase I study of sorafenib to determine the safety, tolerability, pharmacokinetics, and potential efficacy of this agent in 31 Japanese patients with advanced refractory solid tumors. Sorafenib (100-600 mg) was given as a single dose followed by a 7-day wash-out period, and then administrated twice daily (bid… CONTINUE READING
46 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…